We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Koninklijke Philips NV | NYSE:PHG | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.94% | 26.81 | 27.05 | 26.7125 | 27.03 | 1,661,672 | 01:00:00 |
From May 2019 to May 2024
By Sabela Ojea
Koninklijke Philips N.V. said Wednesday that it has received clearance from the U.S. Food and Drug Administration to sell a range of ultrasonic solutions aimed at the control of Covid-19 related lung and cardiac complications.
The Dutch technology company said ultrasound solutions have proved their utility in imaging peripheral lung tissue affected by pneumonia, one of the potential side effects of Covid-19.
"With this regulatory clearance we can offer clear guidance to ensure safe and effective use of ultrasound... At the same time, we are investing significantly to ramp up production globally, including at our ultrasound manufacturing plants in the U.S.," said Bich Le, senior vice president and general manager of Ultrasound at Philips.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 13, 2020 09:27 ET (13:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Koninklijke Philips NV Chart |
1 Month Koninklijke Philips NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
